Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.


Estrella Immunopharma Inc

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.18 Insider Own74.46% Shs Outstand36.38M Perf Week-2.27%
Market Cap36.09M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.29M Perf Month-4.62%
Income-0.63M PEG- EPS next Q- Inst Own0.37% Short Float0.12% Perf Quarter-6.42%
Sales0.00M P/S- EPS this Y- Inst Trans0.09% Short Ratio0.40 Perf Half Y-29.65%
Book/sh0.23 P/B4.27 EPS next Y- ROA-2.28% Short Interest0.01M Perf Year-90.73%
Cash/sh0.13 P/C7.63 EPS next 5Y- ROE-2.51% 52W Range0.86 - 33.00 Perf YTD-10.63%
Dividend Est.- P/FCF- EPS past 5Y- ROI-7.47% 52W High-96.99% Beta0.18
Dividend TTM- Quick Ratio62.34 Sales past 5Y- Gross Margin- 52W Low15.35% ATR (14)0.09
Dividend Ex-Date- Current Ratio62.34 EPS Y/Y TTM-44.10% Oper. Margin0.00% RSI (14)41.97 Volatility7.11% 8.12%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q51.47% Payout- Rel Volume0.87 Prev Close1.00
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume27.84K Price0.99
SMA20-4.96% SMA50-9.08% SMA200-65.13% Trades Volume24,153 Change-0.80%
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.